`Exhibit 1043, Page 1
`Case IPR2015-01069
`
`THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`Mylan Pharmaceuticals Inc., Petitioner
`
`V .
`
`Nissan Chemical Industries Ltd.
`
`Patent Owner
`
`U.S. Patent No. 5,856,336 to Fujikawa er al.
`Issue Date: January 5, 1999
`Title: Quinoline Type Mevalonolactcnes
`
`Inter Parres Review N0.: IPR2015 -01069
`
`DECLARATION OF AMY D. BRODY IN SUPPORT OF
`
`MYLAN PHARMACEUTICALS INC.’S MOTION
`
`FOR PRO HAC VICE ADMISSION (EXHIBIT 1043)
`
`Mail Stop "PA TENT BOARD "
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`
`P.O. Box 1450
`
`Alexandria, VA 223 13-1450
`
`
`
`Mylan Pharmaceuticals Inc.
`Exhibit 1043, Page 2
`Case IPR2015-01069
`
`I, Amy D. Brody, declare as follows:
`
`1.
`
`I am an attorney licensed to practice law in the State of Illinois and am
`
`a partner with the law firm of Rakoczy Molino Mazzochi Siwik LLP, 6 West
`
`Hubbard Street, Suite 500, Chicago, Illinois 60654.
`
`2.
`
`I am an experienced litigator, with nearly fifteen (15) years of
`
`litigation experience, including over ten (10) years of patent litigation experience.
`
`I have represented clients in numerous patent infringement actions in various
`
`technical areas relating to the chemical and pharmaceutical arts.
`
`3.
`
`I am a member in good standing of the Bars of the State of Illinois
`
`(2000) and the District of Columbia (2002).
`
`I am also admitted to practice before
`
`the following courts: United States Court of Appeals for the Federal Circuit
`
`(2004); United States Court of Appeals for the District of Columbia (2004); and
`
`the United States District Court for the Northern District of Illinois (2000).
`
`4.
`
`I have never been suspended or disbarred from practice before
`
`any court or administrative body.
`
`5.
`
`I have never been denied admission to practice before any court
`
`or administrative body.
`
`6.
`
`I have never been subject to sanctions or contempt citations imposed
`
`by any court or administrative body.
`
`
`
`Mylan Pharmaceuticals Inc.
`Exhibit 1043, Page 3
`Case IPR20 l 5-01069
`
`7.
`
`I have read and will comply with Office Patent Trial Practice Guide
`
`and the Board’s Rules of Practice for Trials, as set forth in title 37, part 42 of the
`
`Code of Federal Regulations (C.F.R.).
`
`8.
`
`I agree to be subject to the United States Patent and Trademark
`
`Office Rules of Professional Responsibility set forth in parts 10 and 11 of 37
`
`C.F.R. and to disciplinary jurisdiction under 37 C.F.R. § 1l.l9(a).
`
`I have not
`
`appeared pro hac vice in any proceedings before the United States Patent and
`
`Trademark Office in the past three (3) years.
`
`9.
`
`I have an established familiarity with the subj ect matter -at issue in the
`
`current proceeding, IPR20l5—0l069. Specifically, I have reviewed the challenged
`
`patent, the Petition, the accompanying exhibits and the Preliminary Response
`
`(With accompanying exhibits) to the Petition.
`
`I represent Mylan Pharmaceuticals
`
`Inc. (“Mylan”) in the underlying district court litigation, which involves claims of
`
`non-infringement and invalidity of the patent—at—issue in this Inter Partes Review
`
`(“IPR”). See Kowa Company, Ltd. v. Mylan, Inca, Civil Action No.
`
`l:l4-cv-
`
`02647—PAC (S.D.N.Y. filed Apr. 14, 2014).
`
`I am involved in all aspects of that
`
`pending district court litigation. As a result of my representation of Mylan, I have
`
`acquired substantial understanding of the technology relevant to this IPR.
`
`
`
`Mylan Pharmaceuticals Inc.
`Exhibit 1043, Page 4
`Case IPR201S-01069
`
`I, Al\/IY D. BRODY, hereby declare, under penalty of perjury under 28
`
`U.S.C. § 1746 and the laws of the United States of America, that the foregoing
`
`Declaration is true and correct.
`
`Dated: August 19, 2015
`
`Respectfully submitted,
`
`Amy D. Bro
`(abr0dy@rmmslega1.c0m)
`RAKOCZY MOLINO MAZZOCI-II SIWIK LLP
`
`6 West Hubbard Street, Suite 500
`Chicago, Illinois 60654
`(312) 222-6344 (telephone)
`(312) 222-6345 (facsimile)